223 related articles for article (PubMed ID: 33635506)
1. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Misawa K; Yamaotsu N; Hirono S
J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
[TBL] [Abstract][Full Text] [Related]
2. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
[TBL] [Abstract][Full Text] [Related]
3. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
[TBL] [Abstract][Full Text] [Related]
4. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
5. Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.
Zhu MR; Du DH; Hu JC; Li LC; Liu JQ; Ding H; Kong XQ; Jiang HL; Chen KX; Luo C
Acta Pharmacol Sin; 2018 Feb; 39(2):302-310. PubMed ID: 28858300
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D
Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859
[No Abstract] [Full Text] [Related]
7. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
8. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
10. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
11. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
[TBL] [Abstract][Full Text] [Related]
12. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
15. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
16. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
18. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Zhang KL; Shen QQ; Fang YF; Sun YM; Ding J; Chen Y
Acta Pharmacol Sin; 2019 Dec; 40(12):1587-1595. PubMed ID: 31171828
[TBL] [Abstract][Full Text] [Related]
19. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
[TBL] [Abstract][Full Text] [Related]
20. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
